Due to an adverse event revelation.

The Aim of this study is to validate a treatment of anastrozole in combination with tegafur-uracil as pre-operative therapy for postmenopausal primary breast cancer. Although pre-operative hormone therapy is a novel therapeutic approach, only hormone therapy has limitation in terms of efficacy. Metronomic chemotherapy, which is the frequent administration of low-dose cytotoxic agents, is not only target tumor cells but also inhibiting angiogenesis. Because there was a report that efficacy of hormone therapy add to metronomic chemotherapy as pre-operative therapy, a randomized phase II trial of anastrozole (ANA) in combination with/without metronomic tegafur-uracil (UFT) as neo-adjuvant for postmenopausal breast cancer will be conducted.

Inclusion Criteria:

• Histologically-confirmed diagnosis of invasive breast cancer
• Clinical stage T2, N0 or N1, M0 (TNM Classification)
• Patients must be postmenopausal
• Tumors are estrogen receptor (ER) positive and human epidermal growth factor receptor (HER2) negative
• ECOG Performance status (PS) 0 or 1
• Patients must be able to swallow tablets and capsules
• Candidates for mastectomy or breast-conserving surgery
• Adequate bone marrow, liver and renal function
• Written informed consent was obtained from all patients before randomization.

Exclusion Criteria:

• Inoperable, bilateral or inflammatory breast cancer
• multiple carcinoma
• Personal history of invasive carcinoma
• Patients receive systemic therapy of corticosteroid
• Patients receive estrogen preparation or raloxifene
• Patients with other concurrent severe and/or uncontrolled medical disease
• Patients whom doctors judged inadequate to the enrollment of this study by other reasons.